Brief: Marksans Pharma Says Subsidiary Receives EIR From USFDA
30/06/2025 09:42
June 30 (Reuters) - Marksans Pharma Ltd MARK.NS: MARKSANS PHARMA LTD - SUBSIDIARY RECEIVES EIR FROM USFDA Source text: ID:nNSE1dgT2n Further company coverage: MARK.NS ((reuters.briefs@thomsonreuters.com;))
Recent news on Marksans Pharma
See all newsIndia's Marksans Pharma jumps to over 18-month high after more than doubling quarterly profit
Brief: Marksans Pharma Ltd To Acquire 100% Of Netherlands-Based Qliniq B.V
India's Marksans Pharma jumps to 10-month high after Q4 profit rise
Brief: Marksans Pharma March-Quarter Consol Net Profit 1.48 Billion Rupees
Brief: Marksans Pharma Ltd Receives USFDA Approval For Benzonatate Capsules USP, 100 Mg & 200 Mg